If you have been reading about 稳定性 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
EMPA is employed in monazite geochronology especially for in-situ chemical dating (total-Pb dating). The high content of U, Th and Pb in monazite match with the requirement arising from the relatively higher lower detection limit. Therefore, EMPA is a high-resolution (approximately 1 μm), rapid and inexpensive method in chemical dating to resolve growth histories of monazite. It can achieve a precision of 5–10 myr in Pb-rich monazite, and 10–20 myr in Pb-poor monazite.
K is the clearance [mL/min] CU is the urine concentration [mmol/L] (in the USA often [mg/mL]) Q is the urine flow (volume/time) [mL/min] (often [mL/24 h]) CB is the plasma concentration [mmol/L] (in the USA often [mg/mL]) When the substance "C" is creatinine, an endogenous chemical that is excreted only by filtration, the clearance is an approximation of the glomerular filtration rate. Inulin clearance is less commonly used to precisely determine glomerular filtration rate. Note - the above equation (11) is valid only for the steady-state condition. If the substance being cleared is not at a constant plasma concentration (i.e. not at steady-state) K must be obtained from the (full) solution of the differential equation (9).
The Claisen-Schmidt condensation between 3-(methoxymethoxy)benzaldehyde [13709-05-2] (1) and cyclohexanone (2) afforded CID:54364197 (3). Michael addition of dimethylamine leads the aminoketone, i.e. 2-[dimethylamino-[3-(methoxymethoxy)phenyl]methyl]cyclohexan-1-one, CID21518320. Reduction of the ketone proceeds stereospecifically to afford the cis aminoalcohol [51356-58-2] (4). Mild hydrolysis of the product gives the free phenol ciramadol (5).
=== Filming continued === Much of the Mobile footage shot by Malmuth was scrapped, although a few local landmarks remain visible in the finished film, such as the Bankhead Tunnel. Filming resumed on July 5. Baxley indicated that he wanted to add two weeks to the schedule and reshoot most of the Mobile scenes to set the entire film on the Gulf Coast. Bosworth claimed to have been told that his family scenes would be included, only to see that option abandoned after production ran out of money, having burnt $4 million of a projected $8 million budget on the discarded material. Bosworth, Henrisksen and Forsythe rewrote some or much of their lines, often on the day of filming. As a result of this unexpected freedom, Henriksen remembered the movie as a particularly enjoyable experience despite its overall travails. The Sheer Yachts boatyard in Ocean Springs was transformed to recreate the Brotherhood's hangout, and host a few ancillary scenes. Bosworth suffered a knee injury at the location on July 11, but did not miss any days. Bosworth performed a higher-than-average share of his stunts, including driving his bike during select action sequences. Baxley's father Paul served as stunt coordinator on the film.
Sources: en.wikipedia.org
== Places == Garsdale railway station, England (GB CRS code) Georgia School for the Deaf, Cave Spring, Georgia, United States Harvard Graduate School of Design, Gund Hall, Cambridge, Massachusetts, US
=== Post-Sinestro Corps War === Boodikka becomes a member of the Alpha Lanterns. The Lanterns being enhanced with Manhunter technology, effectively making them cyborgs. Boodikka later falls under the mental control of Cyborg Superman. As she attacks Kyle Rayner, Soranik Natu, and John Stewart, Green Lantern member Hannu ambushes and severely injures her. This temporarily frees Boodikka from Cyborg Superman's control; she instructs the other Lanterns to recharge the battery with the energy she has absorbed. Her fellow Lanterns repair her enough for her to fight, and she joins in the attack on Cyborg Superman's base. During the battle, Cyborg Superman's body is destroyed and his consciousness attempts to take control of Boodikka's body. Boodikka's consciousness fights back, defeating him. On her return to Oa, Boodikka is made a member of the Lantern Honor Guard.
== Physical appearance == Wild type fruit flies are yellow-brown, with brick-red eyes and transverse black rings across the abdomen. The fly's body is divided into three main parts: head, thorax, and abdomen. The head is relatively round and features large, prominent red compound eyes. These eyes are made up of hundreds of ommatidia and occupy most of the head's surface. The brick-red color of the eyes of the wild type fly are due to two pigments: xanthommatin, which is brown and is derived from tryptophan, and drosopterins, which are red and are derived from guanosine triphosphate. Between the eyes are short antennae, which look like tiny feathery or bristled projections and are used for detecting odors, air currents, and vibrations. Drosophila also has bristles—short, stiff hairs—distributed across the head and body, which are useful for tactile sensing.
TA-CD is a vaccine developed by the Xenova Group and designed to negate the effects of cocaine, making it suitable for use in treatment of addiction. It is created by combining norcocaine with inactivated cholera toxin.
The study of catalysis and catalytic reactions is very important to the field of physical organic chemistry. A catalyst participates in the chemical reaction but is not consumed in the process. A catalyst lowers the activation energy barrier (ΔG‡), increasing the rate of a reaction by either stabilizing the transition state structure or destabilizing a key reaction intermediate, and as only a small amount of catalyst is required it can provide economic access to otherwise expensive or difficult to synthesize organic molecules. Catalysts may also influence a reaction rate by changing the mechanism of the reaction.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.